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Abstract
While liposarcoma is the second most common soft tissue malignant tumor, the molecular pathogenesis in this malignancy
is poorly understood. Our goal was therefore to expand the understanding of molecular mechanisms that drive liposarcoma
and identify therapeutically-susceptible genetic alterations. We studied a cohort of high-grade liposarcomas and benign
lipomas across multiple disease sites, as well as two liposarcoma cell lines, using multiplexed mutational analysis. Nucleic
acids extracted from diagnostic patient tissue were simultaneously interrogated for 150 common mutations across 15
essential cancer genes using a clinically-validated platform for cancer genotyping. Western blot analysis was implemented
to detect activation of downstream pathways. Liposarcoma cell lines were used to determine the effects of PI3K targeted
drug treatment with or without chemotherapy. We identified mutations in the PIK3CA gene in 4 of 18 human liposarcoma
patients (22%). No PIK3CA mutations were identified in benign lipomas. Western blot analysis confirmed downstream
activation of AKT in both PIK3CA mutant and non-mutant liposarcoma samples. PI-103, a dual PI3K/mTOR inhibitor,
effectively inhibited the activation of the PI3K/AKT in liposarcoma cell lines and induced apoptosis. Importantly,
combination with PI-103 treatment strongly synergized the growth-inhibitory effects of the chemotherapy drugs
doxorubicin and cisplatin in liposarcoma cells. Taken together, these findings suggest that activation of the PI3K/AKT
pathway is an important cancer mechanism in liposarcoma. Targeting the PI3K/AKT/pathway with small molecule inhibitors
in combination with chemotherapy could be exploited as a novel strategy in the treatment of liposarcoma.
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Introduction
Liposarcoma is the second most common soft tissue malignant
tumor, accounting for 15% of all adult soft tissue sarcomas. The
male to female age ratio at the time of diagnosis is 57 to 43 years,
with the mean age being 51617 years (range 5 to 94 years) [1–4].
Liposarcoma usually arises in lipoblast cells in a deep soft tissue,
such as those inside the thigh or in the retroperitoneum. Patient
survival of liposarcoma is related to the degree of malignancy of
the cell types, localization, and size of the primary tumor and
treatment protocols [2]. According to the World Health Organi-
zation and others, liposarcoma is currently subclassified into four
groups: well differentiated, dedifferentiated, myxoid/round cell,
and pleomorphic [4,5]. In contrast, lipoma is a benign tumor
which is composed of adipose tissue and is the most common form
of soft tissue tumor [6,7]. Although some genetic studies have
provided insight into the mechanism of liposarcoma and lipoma
development, the exact pathogenesis remains largely unknown [8–
10]. Oncogenesis is a multistep process largely involving the
activation of oncogenes and/or the inactivation of tumor
suppressor genes. However, this process has rarely been investi-
gated in liposarcoma relative to lipoma. Interestingly, previous
studies, molecular abnormalities associated with liposarcoma have
been reported, such as amplification of the mdm2 gene and
overexpression of the mdm2 protein emerging as the most
frequent abnormality in dedifferentiated liposarcoma [11–13].
Although HRAS mutations have been reported in malignant
fibrous histiocytoma (MFH), leiomyosarcoma, and rhabdomyo-
sarcoma, HRAS mutation is a relatively uncommon event in
liposarcoma [14]. Furthermore, liposarcomas showed neither
TP53 gene mutations nor altered MYC gene expression [15].
These results indicate that the HRAS and MYC oncogenes and the
TP53 tumor suppressor gene may not play a major role in the
etiology of liposarcomas. In contrast, zebrafish expressing consti-
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tutively active AKT2 in mesenchymal progenitors develop well-
differentiated liposarcoma that closely resembles the human
disease [16]. Recent study has shown activating PIK3CA
mutations were found in 14% of liposarcoma [17]. In a novel
established dedifferentiated liposarcoma xenograft mouse model,
PTEN down-regulation has been shown as a malignant signature
and response to PI3K pathway inhibition [18]. These studies
suggest further identification of critical carcinogenic driver
mechanisms in liposarcoma tumor specimens may predict patient
outcomes and provide potential targets for therapeutic interven-
tion.
For the treatment of liposarcoma, surgical resection remains the
main modality for curative therapy. However, large liposarcomas
in the extremity or retroperitoneal are associated with high local
recurrence (15% and 75%) and poor overall survival [1,3].
Incorporation of neo-adjuvant approaches such as chemotherapy
or radiotherapy may improve local control; however, though little
progress has been made on improving the survival in this disease in
the past 20 years (1, 16). The aim of this study is to identify unique
genetic variations in liposarcoma by using a clinically-validated
SNaPshot cancer genotyping platform that evaluates150 common
hotspot mutations across 15 cancer driver genes [19,20],
ultimately with the overall goal of finding new therapeutically-
relevant targets for liposarcoma patients.
Materials and Methods
Ethic Statement and Liposarcoma Tumor Samples
Fresh-frozen liposarcoma and lipoma patient specimens were
obtained from the clinical archives of the Sarcoma Tumor Bank of
Massachusetts General Hospital. A cohort of 18 high-grade
liposarcomas and 19 benign lipomas obtained across multiple
disease sites were selected for this study. Patient medical record
information was also collected for this study. Institutional review
board approval was obtained from the Partners Human Research
Office (2007P-002464). Patient records/information was anon-
ymized and de-identified prior to analysis.
Cell Lines and Cell Culture
The human liposarcoma cell lines SW872 (an undifferentiated
liposarcoma, ATCC catalog number: HTB-92) and SW982
(another undifferentiated liposarcoma as evaluated by histopathol-
ogy, ATCC catalog number: HTB-93) were purchased from the
ATCC (Rockville, MD). These cell lines were cultured in RPMI
1640 (Invitrogen, Carlsbad, CA) supplemented with 10% FBS,
100 units/ml penicillin and 100 mg/ml streptomycin (Invitrogen).
Cells were incubated at 37uC in a 5% CO2-95% air atmosphere
and passaged when near confluent monolayers were achieved
using Trypsin-EDTA solution. Cells were free of Mycoplasma
contamination, as tested by the MycoAlert Mycoplasma Detection
Kit from Cambrex (Rockland, ME).
Extraction of Genomic DNA
Extraction of DNA from liposarcoma tumor tissues and cell
lines was performed using the QIAamp DNA Micro kit (Qiagen,
Valencia, CA). The extraction was carried out according to the
manufacturer’s instructions. Briefly, liposarcoma tumor tissue
samples (approximately 50 mg) or cell pellets from cultured cell
lines (approximately 8 mg) were transferred to a 1.5 mL micro-
centrifuge tube and 180 mL of buffer ATL (Qiagen) was
immediately added. After equilibrating to room temperature
(25uC), 20 mL of proteinase K was added and mixed by vortexing
for 15 seconds. The sample tube was incubated at 56uC overnight
until the sample was completely lysed. The next day, 200 mL
buffer AL (Qiagen) was added and mixed by vortexing for 15
seconds. Subsequently, 200 mL of ethanol (96%–100%) was
added. The mixture obtained was loaded on a QIAampMiniElute
spin column and washed with AW1 buffer, followed by AW2
buffer (Qiagen). DNA was eluted with 60 mL of bufferAE (Qiagen)
and preserved at 220uC until use. Quantity and quality of the
DNA was determined using a spectrophotometer (DU640, Beck-
man Instruments, Inc, Fullerton, CA) and agarose gel electropho-
resis.
Liposarcoma Genetic Mutation Analysis
A clinically-validated cancer genotyping platform that evalu-
ates150 common hotspot mutations across 15 cancer driver genes
(AKT1, APC, BRAF, CTNNB1, EGFR, ERBB2, IDH1, KIT, KRAS,
MAP2K1, NOTCH1, NRAS, PIK3CA, PTEN, TP53) was employed,
using DNA isolated from frozen human liposarcoma and lipoma
samples. The assay is based on the SNaPshot multiplex platform
(Applied biosystems, Carlsbad, CA), as described previously
[19,20]. Sequence analysis of mutational hotspots mapping within
the PIK3CA adaptor–binding, helical and kinase domains was
conducted by direct sequencing of M13-tagged PCR products
generated using the following primer pairs: PIK3CA exon 1, 59
tgtaaaacgacggccagtTGCTTTGGGACAACCATACA- 39 (for-
ward) and 59-caggaaacagctatgaccttttagaaagggacaacagttaagc-39 (re-
verse); exon 9, 59-TGTAAAACGACGGCCAGTctgtgaatcca-
gaggggaaa-39 (forward) and 59-CAGGAAACAGCTATGACCc-
atgctgagatcagccaaat-39 (reverse); exon 20, 59-tgtaaaacgacggccagt-
catttgctccaaactgacca-39 (forward) and 59 caggaaacagctatgaccTGT-
GGAATCCAGAGTGAGCTT-39 (reverse). Thermocycling was
conducted at 95uC for 8 minutes, followed by 45 cycles of 95uC for
20 seconds, annealing at 58uC (exon 1 and 20) or at 68uC (exon 9)
for 30 seconds and 72uC for 1 minute, and one last cycle of 72uC
for 3 minutes. Sequencing was conducted using the incorporated
M13 primer tag, as previously described [19].
Western Blot Analysis of Phosphoinositide-3-kinase (PI3K)
Pathway Proteins
The human AKT, phosphorylated AKT (pAKT) (threonine
[Thr]308), PI3K p110a, phosphorylated 4E binding protein 1
(p4EBP1) (Thr37/46), BcL-XL, Cytochrome c, caspase 3, mTOR,
phosphorylated mTOR (pmTOR) antibodies were purchased
from Cell Signaling Technologies (Dedham, MA). The mouse
monoclonal antibody to human actin was purchased from Sigma-
Aldrich (St. Louis, MO). Western blot analysis was performed as
previously described, with modifications [21]. Briefly, cells were
lysed in1X radioimmunoprecipitation assay (RIPA) lysis buffer
(Upstate Biotechnology, Lake Placid, NY) and protein concentra-
tion was determined by the DC Protein Assay (Bio-Rad, Hercules,
CA). Total protein (25 mg) was resolved on NuPage 4% to 12%
Bis-Tris gels (Invitrogen, Carlsbad, CA). After electrophoresis,
proteins were transferred to PROTRAN nitrocellulose transfer
membranes (Whatman GmbH, Germany). Membranes were
blocked for 2 hours at 4uC with Odyssey Blocking Buffer (LI-
COR Biosciences, Lincoln, NE), then incubated at 4uC overnight
with primary antibodies diluted in Odyssey Blocking Buffer. After
incubating with primary antibodies, membranes were washed with
TBS-T (containing 0.1% Tween 20) three times, 5 minutes per
each. Membranes were then incubated at room temperature with
rocking for 1 hour with IRDye800CW-conjugated goat anti-rabbit
IgG and IRDye680-conjugated goat anti-mouse IgG secondary
antibodies (LI-COR Biosciences) diluted in Odyssey Blocking
Buffer. Blots were then washed three times with TBS-T and rinsed
with PBS. The levels of expressed proteins were visualized by
PI3K Targeting in Liposarcoma
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scanning the membrane on an Odyssey Infrared Imaging System
(LI-COR Biosciences) with both 700- and 800-nm channels.
Apoptosis Assay
The dual PI3K/AKT and mTOR inhibitor PI-103 (3-(4-(4-
Morpholinyl)pyrido[39,29:4,5]furo[3,2-d]pyrimidin-2-yl]phenol)
was purchased from EMD chemicals, Inc (Gibbstown, NJ) and
dissolved in DMSO. Liposarcoma lines SW872 and SW982 were
seeded at 8000 cells/per well in a 96-well plate for 24 hours before
treatment with different concentrations of PI-103 for 48 hours.
The cells were then lysed by adding 10 ml of 10% NP-40 per well.
Apoptosis was evaluated by a caspase-cleaved keratin 18-based
quantification kit (M30-Apoptosense ELISA assay), as per
manufacturer’s instructions (Peviva AB, Bromma, Sweden). This
assay detects the 21-kDa fragment of cytokeratin 18 that is only
revealed after caspase cleavage of the protein. M30-Apoptosense
ELISA kit has been used for both epithelial (ovarian cancer) and
non epithelial (osteosarcoma) cells apoptosis assays [22,23].
Apoptosis was also evaluated by Western blot using whole-cell
lysates immunoblotted with specific antibodies to PARP (Cell
Signaling Technologies, Cambridge, MA) and its cleavage
products.
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium Bromide) Cytotoxicity Assay
PI-103 and chemotherapy drug cytotoxicity was assessed in vitro
using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) assay. Briefly, 26103 cells per well were plated in
96-well plates in culture medium (RPMI 1640 supplemented with
10% fetal bovine serum and penicillin/streptomycin) and treated
with 0.5 mM PI-103, 0.5 mM doxorubicin, 1 mM cisplatin or a
combination of either of the cytotoxics and PI-103. After 4 days of
culture, 10 ml of MTT (Sigma-Aldrich, 5 mg/ml in PBS) was
added to each well and the plates were incubated for 4 h. The
resulting formazan product was dissolved with HCL-isopropanol
and the absorbance at a wavelength of 490 nm (A490) was read on
a SPECTRAmaxR Microplate Spectrophotometer (Molecular
Devices).
Statistical Analysis
GraphPad PRISM1 4 software from GraphPad Software, Inc.
was used to statistically analyze the data. Errors were SD of
averaged results and p values ,0.05 were accepted as a significant
difference between means.
Results
Liposarcoma Patients and Samples
We identified 18 cases of liposarcoma and 19 cases of lipoma
with sufficient tissues for molecular analysis from the clinical
archives of the Sarcoma Tumor Bank at the Massachusetts
General Hospital (Table. 1). The most common type of
liposarcoma in this cohort was myxoid, at a frequency of 56%
(n= 10). There were also 2 samples each for the well-differenti-
ated, pleiomorphic, dedifferentiated and mixed liposarcoma
subtypes (Table. 1). The median patient age at disease appearance
was 51 years (range, 20 to 74 years) and 21 (57%) patients were
male and 16 (43%) were female.
Identification of PIK3CA Mutation in Liposarcoma
Mutational profiling was performed on the liposarcoma and
lipoma patient samples, querying for 150 known somatic driver
mutations. A BRAF V600E (1799T.A) and PTEN deletion was
found in the liposarcoma cell line SW872, as previously described
(http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action =
sample&name = SW872). No mutations were found in any of the
patient lipoma samples. Conversely, activating mutations in the
PIK3CA gene (PI3-kinase, p110 alpha subunit) were observed in
four cases (22%) of liposarcoma (Figure 1) One tumor sample
(Patient #203, female) harbored the E542K (1624G.A)
mutation located with the helical domain of PIK3CA, and
three cases (Patient #166, 1000, 1001, all male) carried the
H1047R (3140A.G) mutation located with the PIK3CA kinase
domain. All four PIK3CA mutations were identified in myxoid
liposarcoma out of 10 total samples with this histological subtype
(33%).
Table 1. Characteristics of Patients with Liposarcoma and Lipoma (n= 37).
Characteristics Numbers Percentage PIK3CA Mutation
Age at diagnosis, years
Median 51 N/A
Range 20–74 N/A
Sex
Male 21 57
Female 16 43
Liposarcoma 18 49
Well-differentiated 2 11 0
Myxoid 10 56 4
Pleiomorphic 2 11 0
Dedifferentiated 2 11 0
Mixed 2 11 0
Lipoma 19 51 0
Recurrence 2 11
Metastasis 3 17
doi:10.1371/journal.pone.0093996.t001
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Activation of the PI3K Pathway in Liposarcoma Tumor
Tissues
The human PI3K proteins are heterodimeric molecules
composed of a regulatory and a catalytic subunit. PIK3CA is the
gene coding for the p110a protein of PI3K that is a class I PI3K
catalytic subunit [24]. AKT is a major downstream effector of
PI3K and AKT/mTOR activation and can regulate a number of
cellular processes that drive the tumorigenic process, such as
inhibition of apoptosis, expression of survival genes, cell cycle
progression, protein translation, and cell growth and proliferation
[17,24,25]. Western blot analysis was used to determine the
relative extent of PI3K pathway activation in 2 liposarcoma cases
that carried an activating PIK3CA mutation compared with 3
liposarcoma samples for which PIK3CA mutations were not
observed, as well as 3 lipoma samples (Figure 2). Because it is
known that PI3K activates both the AKT and mTOR pathways,
the relative levels of pAKT protein was used to gauge AKT
activity and levels of p4EBP1 was used as an indicator mTOR
activity. Using this strategy, only 1 out of 3 lipoma samples
demonstrated pathway activity as evidenced by elevated levels of
pAKT and p4EBP1. Conversely, 2 out of 2 PIK3CA-mutant and 2
out of 3 PIK3CA-wild type liposarcoma samples demonstrated high
levels of pAKT. Furthermore, all 5 liposarcoma samples revealed
highly expressed p4EBP1, regardless of PIK3CA mutational status.
These data suggest that activation of AKT/mTOR signaling is
likely an essential tumorigenic driver, where PIK3CA gene
mutation may serve as one of several mechanism of pathway
activation.
Inhibition of PI3K Pathway Proteins by PI-103 in
Liposarcoma Cell Lines
Although the two liposarcoma cell lines SW872 and SW982 did
not show PIK3CA mutation by mutational profiling, both cell lines
exhibited high baseline levels of PI3K signaling (Figure 3).
Western blot analysis demonstrated that exposure to PI-103, a
dual inhibitor of AKT and mTOR [26,27], reduced AKT
phosphorylation (pAKT) and 4EBP1 phosphorylation (p4EBP1)
in a dose-dependent manner in both cell lines (Figure 3). In
addition, expression levels of the anti-apoptosis protein BcL-XL
was also reduced by PI-103. pmTOR was not inhibited by PI-103
at the doses given.
Figure 1. Mutational profiling of liposarcoma in four patients using a clinical mutational profiling assay. DNA was extracted from
human liposarcoma and lipoma specimens and were evaluated for somatic mutations across 15 essential cancer genes (150 point mutations). The
four sections on the bottom (B) are portions of the electropherogram that identify the PIK3CA gene mutations identified across 4 patient liposarcoma
samples. For reference, each section is accompanied by genotyping data obtained from a non-cancerous control sample directly above each patient’s
plot (A).
doi:10.1371/journal.pone.0093996.g001
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Induction of Apoptosis by PI-103 in Liposarcoma Cell
Lines
The effect of PI-103 on the induction of apoptosis in
liposarcoma cell lines SW872 and SW982 was assessed by M-
30-Apoptosense ELISA and by evaluating PARP cleavage. PARP
cleavage was detected 24 hours following incubation with PI-103
(Figure 4A). A dose-response analysis revealed the appearance of
PARP cleavage products in the presence of 0.1 mmol of PI-103
Figure 2. Western blot analysis of PI3K pathway protein expression levels of PI3K p110a, AKT, pAKT (Thr308), p4EBP1 (Thr37/46) in
liposarcoma and lipoma tissues. For Western blot analysis, 25 mg of cellular proteins was subjected to immunoblotting with specific antibodies
as described in Materials and Methods.
doi:10.1371/journal.pone.0093996.g002
Figure 3. Effects of PI-103 on PI3K/mTOR in liposarcoma cell lines. SW872 and SW982 cells were treated with different concentrations of PI-
103 for 24 hours. The effects of PI-103 on PI3K/mTOR pathway protein expression levels were determined by West blot analysis. Note the significant
decrease in pAKT and p4EBP1 expression in both of liposarcoma cell lines post PI-103 treatment.
doi:10.1371/journal.pone.0093996.g003
PI3K Targeting in Liposarcoma
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when the cells were allowed to incubate for 24 hours Treatment of
liposarcoma cells with PI-103 also showed moderate effect on
cytochrome c release (Figure 4B).
Synergistic Effect of PI-103 on Cisplatin and Doxorubicin
Sensitivity in Liposarcoma Cell Lines
Constitutive activation of PI3K/mTOR signaling may contrib-
ute to the survival advantage of human cancer cells, in part
through the induction of antiapoptotic regulatory proteins. We
hypothesized that inhibition of AKT/mTOR pathway in liposar-
coma would lower the apoptotic threshold and increase chemo-
therapy sensitivity. To investigate this, liposarcoma cell lines
SW872 and SW982 were treated with either PI-103 (0.5 mmol)
alone, chemotherapy drug (cisplatin or doxorubicin) alone, or the
combination of chemotherapy drug and PI-103 for 48 hours. The
data showed that the addition of PI-103 to these liposarcoma cell
lines concurrently exposed to either cisplatin or doxorubicin
resulted in a synergistic effect on cell growth inhibition in
liposarcoma cells (Figure 5).
Discussion
Identification of specific genetic changes in liposarcoma may
help develop potential targeted therapy approaches using small-
molecule inhibitors. We compared 37 liposarcoma or lipoma
patient tumor tissue samples using a site-directed mutational
profiling platform that has been implemented for clinical tumor
genotyping. The characteristics of clinical and pathologic samples
of liposaroma in this study are similar to those described in our
previously published studies [3]. Among the 150 common
mutations that were evaluated across 15 oncogene and tumor
suppressor genes in the screening panel, the PIK3CA gene, which
encodes the p110 alpha subunit of PI3K, was the only gene that
was found to be mutated in liposarcoma tissues.
The PI3K pathway is widely dysregulated in human cancer and
many studies have shown this pathway to be vital to the growth
and survival of cancer cells [24,25]. Multiple mechanisms have
been found to induce PI3K signaling, such as activating mutation
or amplification of key genes in this pathway (PIK3CA and AKT1)
or loss of function of the negative modulator PTEN [28,29]. PTEN
down-regulation has been shown as a malignant signature in
liposarcoma and response to PI3K pathway inhibition either with
rapamycin alone or in combination with the multikinase inhibitor
sorafenib [18]. PI3K can also be activated by upstream receptor
tyrosine kinases (RTKs) [24,25]. Aberrant AKT activation has
also been shown in a zebrafish model of well-differentiated
liposarcoma [5]. For these reasons, several small molecular
inhibitors that target the PI3K/AKT signaling pathway have
been tested using both in vitro and in vivo cancer models [24,25].
In our study, activating mutations in the PIK3CA gene were
found in 4 out of 18 human liposarcoma samples (22%) and in
none of the 19 benign lipomas or the liposarcoma cell lines tested.
These data are comparable with previously reports showing a
PIK3CA mutation rate of 14–18% in myxoid/round-cell liposar-
comas [17,30]. The PIK3CAmutations in were also associated with
AKT activation and poor clinical outcomes [30]. Interestingly, in
our current study, AKT and mTOR activation were also seen in
PIK3CA non-mutant liposarcoma samples. As PI3K signaling is
activated in human cancers via several different mechanisms, these
data suggest that alternative mechanisms other than PIK3CA
mutation are also important for PI3K activation in liposarcoma.
Further investigations are required to identify these alternative
mechanisms, which could include PTEN or RTK status in these
PIK3CA non-mutant liposarcomas. Taken together, these findings
suggest that activation of the AKT/mTOR pathway in liposar-
coma can occur either through activating PIK3CA gene mutations
or by alternative cancer mechanisms.
Figure 4. PI3K/mTOR inhibitor PI-103 induces apoptosis in liposarcoma cells. SW872 and SW982 cells were treated with different
concentration of PI-103 for 48 hours. The apoptotic effects of PI-103 on liposarcoma cells were determined by M-30-Apoptosense ELISA kit and
Western blot analysis of PARP cleavage. (A) M30-Apoptosense ELISA assay was done as described in Materials and Methods. (B) Total cellular proteins
were subjected to immunoblotting with specific antibodies to PARP and b-actin as described in Materials and Methods.
doi:10.1371/journal.pone.0093996.g004
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We recognize the limitations of our clinical genotyping strategy
where many other important mutations or tumor drivers are not
detected [19]. The mutational profiling platform utilized was
developed to simultaneously query across 150 site-specific
mutations that are commonly mutated in cancer and have
therapeutic implications. Therefore, alternative genetic mecha-
nisms that are less frequent or have uncertain clinical benefit were
not evaluated. These may include gene amplification, insertion,
deletion or translocation (eg, FUS-CHOP or EWS-CHOP), as
well as mutation in other cancer genes.
Western blot analysis confirmed the downstream activation of
AKT in both PIK3CA mutant and non-mutant liposarcoma
samples, supporting this pathway’s importance in liposarcoma
tumorigenesis. Another new approach of our study is to inhibit
PIK3 signaling with a dual inhibitor of PI3K/mTOR in
liposarcoma. PI-103 effectively inhibited the activation of PI3K/
AKT in liposarcoma cell lines and induced apoptosis. The
magnitude of effects on survival was similar to that seen with
treatment using chemotherapy. Importantly, when PI-103 and
chemotherapy were combined, strong synergistic activity was
noted. The results suggest PI-103 may lower the apoptotic
threshold of chemotherapy drug in liposarcoma cells by targeting
PIK/AKT. PI-103 has been used in preclinical studies and has
demonstrated promising inhibitory results for various types of
cancer [27,31–33]. A more recent study also showed treatment of
liposarcoma xenograft models with either the PI3K/AKT/
mTOR pathway inhibitor rapamycin alone or in combination
with the multi-kinase inhibitor sorafenib, all xenografts responded
with increased lipid content and a more differentiated gene
expression profile [34].
In conclusion, as the exact efficacy of chemotherapy in
liposarcoma has not been clearly established, with the failure rate
being high [1,35], the results showed of this study suggest that
chemotherapy drugs, when combined with PIK3 inhibitor PI-103
combination may prove an effective approach for the treatment of
liposarcoma.
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Figure 5. Synergistic effects of PI3K/mTOR inhibitor PI-103 on chemotherapy drug in liposarcoma cell lines. (A) SW872 or SW982 cells
was exposed to combinations of cisplatin/PI-103. The combination caused a synergistic increase in the cell death. (B) SW872 or SW982 cells was
exposed to combinations of doxorubicin/PI-103. The combination also caused a synergistic increase in the cell death.
doi:10.1371/journal.pone.0093996.g005
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